MARKET

GDTC

GDTC

CytoMed Therapeutics Ltd
NASDAQ
1.510
+0.100
+7.09%
Opening 12:07 12/31 EST
OPEN
1.450
PREV CLOSE
1.410
HIGH
1.590
LOW
1.450
VOLUME
19.82K
TURNOVER
--
52 WEEK HIGH
4.050
52 WEEK LOW
1.380
MARKET CAP
17.72M
P/E (TTM)
-6.0376
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GDTC last week (1222-1226)?
Weekly Report · 2d ago
Weekly Report: what happened at GDTC last week (1215-1219)?
Weekly Report · 12/22 09:57
Weekly Report: what happened at GDTC last week (1208-1212)?
Weekly Report · 12/15 10:03
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 12/09 12:05
CytoMed Therapeutics Partners with Malaysian Hospital for Groundbreaking Cancer Trial
TipRanks · 12/08 13:28
Cytomed Therapeutics enters into MoU with UMMC
TipRanks · 12/08 13:16
CytoMed Therapeutics Enters Into MOU With UMMC To Establish Phase I Clinical Trial To Investigate Safety And Efficacy Of CytoMed's Patented Allogeneic Unmodified Gamma Delta T Cells For No-Option Cancer Patients In Malaysia
Benzinga · 12/08 13:08
Weekly Report: what happened at GDTC last week (1201-1205)?
Weekly Report · 12/08 10:02
More
About GDTC
CytoMed Therapeutics Limited is a biopharmaceutical company. It is focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and gamma delta Natural Killer T cel to create cell-based immunotherapies for the treatment of human cancers. The development of its technologies has been inspired by the clinical success of existing CAR-T in treating hematological malignancies as well as the clinical limitations and commercial challenges in extrapolating the CAR-T principle into treatment of solid tumors. Its product candidates include CTM-N2D, iPSC-gdNKT, and CTM-GDT. CTM-N2D is a lead product candidate that consists of expanded gamma delta T cells grafted with NKG2DL-targeting CAR to enhance anti-cancer cytotoxicity. The iPSC-gdNKT product candidate utilizes iPSC as a starting material to generate gdNKT, which is a synthetic hybrid of a gamma delta T cell and a NK cell. The Company also has the allogeneic gamma delta T cell technology, namely TCB-002.

Webull offers CytoMed Therapeutics Ltd stock information, including NASDAQ: GDTC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GDTC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GDTC stock methods without spending real money on the virtual paper trading platform.